Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease (HPV-kind)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2014 by UMC Utrecht.
Recruitment status was:  Recruiting
National Institute for Public Health and the Environment (RIVM)
Information provided by (Responsible Party):
N.M. Wulffraat, UMC Utrecht Identifier:
First received: December 24, 2008
Last updated: July 29, 2014
Last verified: July 2014

In the Netherlands, the human Papillomavirus (HPV) vaccination will be added to the National Vaccination Program for girls to protect against the development of cervical cancer. The vaccine protects against HPV type 16 & 18, which cause about 75% of cervical cancer. Studies have shown that the vaccine is effective in healthy subjects in preventing infection by HPV 16 & 18. However, no evidence exists on the immunogenicity and safety of HPV vaccination in patients with an immune system disorder, such as primary humoral immunodeficiency (i.e. hypogammaglobulinemia) or autoimmune diseases. Concerns exist that vaccination may cause an aggravation of the underlying disease. In addition, the immune response to vaccination may be diminished due to immunosuppressive therapy or the underlying disease.

Objective: The primary goal of the current study is to study the immunogenicity of HPV vaccination in patients with an autoimmune disease and a primary humoral immunodeficiency.

Based on retrospective analysis with other vaccines we hypothesize that patients with autoimmune diseases who are under immunosuppressive medication and patients with a immune system disorder have a decreased serological response to HPV vaccination, and that the produced HPV antibodies titers decrease more rapidly than in healthy individuals.

The secondary objective is to explore safety of HPV vaccination and immune regulatory mechanisms induced by vaccination in a subset of patients. The investigators hypothesize that HPV vaccination is safe and that HPV-induced regulatory T cells are able to prevent an increase in the activity of an autoimmune disease.

Condition Intervention Phase
Juvenile Idiopathic Arthritis
Systemic Lupus Erythematosus
Juvenile Dermatomyositis
Drug: Human papilloma virus vaccine (cervarix)
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease

Resource links provided by NLM:

Further study details as provided by UMC Utrecht:

Primary Outcome Measures:
  • the immunogenicity of HPV vaccination in patients with immune system disorders. The immunogenicity of HPV vaccination in patients will be compared to healthy controls, measured by antibody levels against HPV serotype 16 & 18. [ Time Frame: 0, 3, 7, 12 months ]

Secondary Outcome Measures:
  • difference in the activity of underlying disease before versus after vaccination. A difference in the activity of underlying autoimmune disease, will be measured according to specific criteria for each autoimmune disease. [ Time Frame: 0,3,7,12 months ]

Estimated Enrollment: 330
Study Start Date: February 2009
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Human papilloma virus vaccine (cervarix)
    vaccination at 0, 1 and 6 months
    Other Name: Cervarix vaccine (GlaxoSmithKLine)
Detailed Description:

Study design: prospective observational cohort study.

Study population: Females aged 12 - 18 years with one of the autoimmune diseases Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE) and Juvenile Dermatomyositis (JDM) are included. Included females are treated at the rheumatology unit from the University Medical Center Utrecht. A small control group of healthy girls aged 13 -17 years will also be included to compare the kinetics of HPV serology with healthy individuals.

Intervention: Starting from September 2009 all girls aged 12 years will be offered a HPV vaccination via the National Vaccination Program. Prior to this, a national campaign will be started in March 2009 to vaccinate all girls aged 13-17 years at once.We will use this national vaccination campaign as an opportunity to analyze the serological response and safety of this vaccine in a large group of with an immune system disorder. The vaccines are administered by our national health organisation. The effects are monitored in our clinics.

Main study parameters/endpoints:

  • Primary outcome immunogenicity is measured by antibody levels against HPV serotype 16 & 18 over time. We consider HPV vaccination to be immunogenic at antibody titers above the cutoffs 20 and 24 mMU/ml for HPV 16 and 18, respectively; or at a ≥2 fold increase in antibody levels against both serotypes. The antibody levels will be measured prior to vaccination, and after 3,7 and 12 months.
  • The secondary outcome is safety of vaccination, measured as activity of the underlying autoimmune disease. In addition, frequency of common adverse effects, and immunological changes induced by HPV vaccination, such as number and function of cytotoxic T cells and Tregs will be described.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Burden: included patients will be asked to visit the hospital 4 times in a period of 12 months. During these visits, physical examination will be performed and blood will be obtained for serological and immunological analysis. Most of these visits are combined with routine follow-up and venous punctures of the patients. However, one extra visit to the hospital and vena puncture is expected. 5 ml (extra) blood is obtained four times from all patients for serological analysis. Included healthy controls will be asked to visit one plenary information meeting in the evening. Controls will have a venous punctures four times during the study, during which 5 ml of blood is obtained. These samples will be obtained at the hospital during evening clinics or at school. In a subset of patients (n=50) and healthy controls (n=10), an additional 15 ml is obtained for immunological analysis.

Risks: participants may experience adverse events of the HPV vaccination. Benefits: Protection against human Papillomavirus infection and therefore reduced risk of cervix carcinoma, certainty about protection against HPV 16 & 18 and about safety of HPV vaccination.

Group relatedness: This study can only be done in patients who need this vaccination (i.e. females in the age group 12-24 years) and have an immune system disorder, such as JIA, SLE or JDM. Appropriate comparison with healthy controls must be performed in age-matched healthy females who are also recruited for the National HPV vaccination campaign, in this case girls in the age group 13-17 years.


Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Females
  • Clinical diagnosis of JIA, SLE or JDM
  • And who are in the following age groups:

    • 12 years (these girls are vaccinated via the National Vaccination Program from September 2009)
    • 13-18 years (these girls are vaccinated during a national vaccination campaign from March-May 2009)
  • Current co-medication: all co-medication prescribed may be continued
  • And in the control group: healthy girls aged 13-17 years (these girls are vaccinated during a national vaccination campaign from March-May 2009)

Exclusion Criteria:

  • No HPV vaccination
  • Refusal to allow venous puncture
  • Proven or suspected cervical carcinoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00815282

Contact: Nico M Wulffraat, MD (31)887554003
Contact: Marloes W Heijstek, MD (31)887554003

University Medical center Groningen Recruiting
Groningen, Netherlands, 9700RB
Contact: Wineke Armbrust, MD    (31)503614404   
Principal Investigator: Wineke Armbrust, MD         
Erasmus Medical Center Rotterdam Recruiting
Rotterdam, Netherlands, 3000CB
Contact: Sylvia M Kamphuis, MD    (31)10-4636104   
Principal Investigator: Sylvia Kamphuis, MD         
UMC Utrecht, department of pediatrics Recruiting
Utrecht, Netherlands, 3508AB
Principal Investigator: Nico M Wulffraat, MD         
Sub-Investigator: Marloes W Heijstek, MD         
Sponsors and Collaborators
N.M. Wulffraat
National Institute for Public Health and the Environment (RIVM)
Principal Investigator: Nico M Wulffraat, MD, PhD UMC Utrecht
Study Director: Fiona van der KLis, MD, PhD National Institute for Public Health and the Environment
Study Director: Guy Berbers, PhD National Institute for Public Health and the Environment
  More Information

Responsible Party: N.M. Wulffraat, MD, UMC Utrecht Identifier: NCT00815282     History of Changes
Other Study ID Numbers: NL26.113.000.08
EUDRACT number 2008-008169-36
Study First Received: December 24, 2008
Last Updated: July 29, 2014

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Arthritis, Juvenile
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Muscular Diseases
Neuromuscular Diseases
Nervous System Diseases
Skin Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on May 25, 2017